Literature DB >> 19286630

Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity.

Ashley J Wilhelm1, Manal Zabalawi, Jason M Grayson, Ashley E Weant, Amy S Major, John Owen, Manish Bharadwaj, Rosemary Walzem, Lawrence Chan, Kazuhiro Oka, Michael J Thomas, Mary G Sorci-Thomas.   

Abstract

OBJECTIVE: The purpose of this study was to determine the effects of an atherogenic diet on immune function in LDLr(-/-), ApoA-I(-/-) mice. METHODS AND
RESULTS: When LDLr(-/-), ApoA-I(-/-) (DKO), and LDLr(-/-) (SKO) mice were fed an atherogenic diet, DKO had larger peripheral lymph nodes (LNs) and spleens compared to SKO mice. LNs were enriched in cholesterol and contain expanded populations of T, B, dendritic cells, and macrophages. Expansion of all classes of LN cells was accompanied by a approximately 1.5-fold increase in T cell proliferation and activation. Plasma antibodies to dsDNA, beta2-glycoprotein I, and oxidized LDL were increased in DKO, similar to levels in diet-fed Fas(lpr/lpr) mice, suggesting the development of an autoimmune phenotype. Both LN enlargement and cellular cholesterol expansion were "prevented" when diet-fed DKO mice were treated with helper dependent adenovirus expressing apoA-I. Independent of the amount of dietary cholesterol, DKO mice consistently showed lower plasma cholesterol than SKO mice, yet greater aortic cholesterol deposition and inflammation.
CONCLUSIONS: ApoA-I prevented cholesterol-associated lymphocyte activation and proliferation in peripheral LN of diet-fed DKO mice. A approximately 1.5-fold increase in T cell activation and proliferation was associated with a approximately 3-fold increase in concentrations of circulating autoantibodies and approximately 2-fold increase in the severity of atherosclerosis suggesting a common link between plasma apoA-I, inflammation, and atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19286630      PMCID: PMC2761013          DOI: 10.1161/ATVBAHA.108.183442

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  39 in total

1.  Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus.

Authors:  Aleksandar K Stanic; Charles M Stein; Adam C Morgan; Sergio Fazio; MacRae F Linton; Edward K Wakeland; Nancy J Olsen; Amy S Major
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-24       Impact factor: 11.205

Review 2.  The immune response in atherosclerosis: a double-edged sword.

Authors:  Göran K Hansson; Peter Libby
Journal:  Nat Rev Immunol       Date:  2006-06-16       Impact factor: 53.106

3.  Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes.

Authors:  N Hyka; J M Dayer; C Modoux; T Kohno; C K Edwards; P Roux-Lombard; D Burger
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

Review 4.  ABCA1-deficient mice: insights into the role of monocyte lipid efflux in HDL formation and inflammation.

Authors:  Robert J Aiello; Dominique Brees; Omar L Francone
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-01-09       Impact factor: 8.311

Review 5.  Autoimmunity, oxidized LDL and cardiovascular disease.

Authors:  Johan Frostegård
Journal:  Autoimmun Rev       Date:  2002-08       Impact factor: 9.754

6.  Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice.

Authors:  Eugene Trogan; Jonathan E Feig; Snjezana Dogan; George H Rothblat; Véronique Angeli; Frank Tacke; Gwendalyn J Randolph; Edward A Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-01       Impact factor: 11.205

7.  Loss of ABCG1 results in chronic pulmonary inflammation.

Authors:  Angel Baldán; Aldrin V Gomes; Peipei Ping; Peter A Edwards
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

8.  Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease.

Authors:  Tamar Aprahamian; Ian Rifkin; Ramon Bonegio; Bénédicte Hugel; Jean-Marie Freyssinet; Kaori Sato; John J Castellot; Kenneth Walsh
Journal:  J Exp Med       Date:  2004-04-19       Impact factor: 14.307

9.  Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE.

Authors:  Michelle N Bradley; Cynthia Hong; Mingyi Chen; Sean B Joseph; Damien C Wilpitz; Xuping Wang; Aldons J Lusis; Allan Collins; Willa A Hseuh; Jon L Collins; Rajendra K Tangirala; Peter Tontonoz
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

10.  Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production?

Authors:  Barry Bresnihan; Martina Gogarty; Oliver FitzGerald; Jean-Michel Dayer; Danielle Burger
Journal:  Arthritis Res Ther       Date:  2004       Impact factor: 5.156

View more
  61 in total

Review 1.  Crosstalk between reverse cholesterol transport and innate immunity.

Authors:  Kathleen M Azzam; Michael B Fessler
Journal:  Trends Endocrinol Metab       Date:  2012-03-10       Impact factor: 12.015

2.  Dysfunctional HDL containing L159R ApoA-I leads to exacerbation of atherosclerosis in hyperlipidemic mice.

Authors:  Mary G Sorci-Thomas; Manal Zabalawi; Manish S Bharadwaj; Ashley J Wilhelm; John S Owen; Bela F Asztalos; Shaila Bhat; Michael J Thomas
Journal:  Biochim Biophys Acta       Date:  2011-09-14

3.  High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide.

Authors:  Masashi Suzuki; David K Pritchard; Lev Becker; Andrew N Hoofnagle; Natsuko Tanimura; Theo K Bammler; Richard P Beyer; Roger Bumgarner; Tomas Vaisar; Maria C de Beer; Frederick C de Beer; Kensuke Miyake; John F Oram; Jay W Heinecke
Journal:  Circulation       Date:  2010-10-25       Impact factor: 29.690

4.  Deficiency of scavenger receptor BI leads to impaired lymphocyte homeostasis and autoimmune disorders in mice.

Authors:  Hong Feng; Ling Guo; Dan Wang; Haiqing Gao; Guihua Hou; Zhong Zheng; Junting Ai; Oded Foreman; Alan Daugherty; Xiang-An Li
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11       Impact factor: 8.311

5.  High-density lipoprotein attenuates Th1 and th17 autoimmune responses by modulating dendritic cell maturation and function.

Authors:  Ioanna Tiniakou; Elias Drakos; Vaios Sinatkas; Miranda Van Eck; Vassilis I Zannis; Dimitrios Boumpas; Panayotis Verginis; Dimitris Kardassis
Journal:  J Immunol       Date:  2015-04-13       Impact factor: 5.422

Review 6.  How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis?

Authors:  Francine K Welty
Journal:  Curr Cardiol Rep       Date:  2013-09       Impact factor: 2.931

7.  High density lipoprotein protects against polymicrobe-induced sepsis in mice.

Authors:  Ling Guo; Junting Ai; Zhong Zheng; Deborah A Howatt; Alan Daugherty; Bin Huang; Xiang-An Li
Journal:  J Biol Chem       Date:  2013-05-08       Impact factor: 5.157

8.  Cholesterol Accumulation in Dendritic Cells Links the Inflammasome to Acquired Immunity.

Authors:  Marit Westerterp; Emmanuel L Gautier; Anjali Ganda; Matthew M Molusky; Wei Wang; Panagiotis Fotakis; Nan Wang; Gwendalyn J Randolph; Vivette D D'Agati; Laurent Yvan-Charvet; Alan R Tall
Journal:  Cell Metab       Date:  2017-05-04       Impact factor: 27.287

Review 9.  High-density lipoprotein affects antigen presentation by interfering with lipid raft: a promising anti-atherogenic strategy.

Authors:  S-H Wang; S-G Yuan; D-Q Peng; S-P Zhao
Journal:  Clin Exp Immunol       Date:  2010-01-06       Impact factor: 4.330

10.  Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice.

Authors:  Catherine Martel; Wenjun Li; Brian Fulp; Andrew M Platt; Emmanuel L Gautier; Marit Westerterp; Robert Bittman; Alan R Tall; Shu-Hsia Chen; Michael J Thomas; Daniel Kreisel; Melody A Swartz; Mary G Sorci-Thomas; Gwendalyn J Randolph
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.